ation, RNA expression, and other comprehensive datasets from primary human cancer tissue. TCGA has served as an invaluable resource for the identification of genomic aberrations, altered transcriptional networks, and cancer subtypes. Nonetheless, the gene regulatory landscapes of these tumors have largely been inferred through indirect means.
RATIONALE: A hallmark of active DNA regulatory elements is chromatin accessibility. Eukaryotic genomes are compacted in chromatin, a complex of DNA and proteins, and only the active regulatory elements are accessible by the cell's machinery such as TFs. The assay for transposase-accessible chromatin using sequencing (ATAC-seq) quantifies DNA accessibility through the use of transposase enzymes that insert sequencing adapters at these accessible chromatin sites. ATAC-seq enables the genomewide profiling of TF binding events that orchestrate gene expression programs and give a cell its identity.
RESULTS : We generated high-quality ATACseq data in 410 tumor samples from TCGA, identifying diverse regulatory landscapes across 23 cancer types. These chromatin accessibility profiles identify cancer-and tissue-specific DNA regulatory elements that enable classification of tumor subtypes with newly recognized prognostic importance. We identify distinct TF activities in cancer based on differences in the inferred patterns of TF-DNA interaction and gene expression. Genome-wide correlation of gene expression and chromatin accessibility predicts tens of thousands of putative interactions between distal regulatory elements and gene promoters, including key oncogenes and targets in cancer immunotherapy, such as MYC, SRC, BCL2, and PDL1. Moreover, these regulatory interactions inform known genetic risk loci linked to cancer predisposition, nominating biochemical mechanisms and target genes for many cancer-linked genetic variants. Lastly, integration with mutation profiling by wholegenome sequencing identifies cancer-relevant noncoding mutations that are associated with altered gene expression. A single-base mutation located 12 kilobases upstream of the FGD4 gene, a regulator of the actin cytoskeleton, generates a putative de novo binding site for an NKX TF and is associated with an increase in chromatin accessibility and a concomitant increase in FGD4 gene expression.
CONCLUSION:
The accessible genome of primary human cancers provides a wealth of information on the susceptibility, mechanisms, prognosis, and potential therapeutic strategies of diverse cancer types. Prediction of interactions between DNA regulatory elements and gene promoters sets the stage for future integrative gene regulatory network analyses. The discovery of hundreds of noncoding somatic mutations that exhibit allele-specific regulatory effects suggests a pervasive mechanism for cancer cells to manipulate gene expression and increase cellular fitness. These data may serve as a foundational resource for the cancer research community.
C
ancer is a highly heterogeneous group of diseases, with each tumor type exhibiting distinct clinical features, patient outcomes, and therapeutic responses. The Cancer Genome Atlas (TCGA) was established to characterize this heterogeneity and understand the molecular underpinnings of cancer (1) . Through large-scale genomic and molecular analyses, TCGA has revealed an exquisite diversity of genomic aberrations, altered transcriptional networks, and tumor subtypes that have engendered a more comprehensive understanding of disease etiologies and laid the foundations for new therapeutics and impactful clinical trials.
Work from TCGA and many others has demonstrated the importance of the epigenome to cancer initiation and progression (2) . Profiling of cancer-specific coding mutations through wholeexome sequencing has identified prominent driver mutations in genes encoding chromatin remodeling enzymes and modifiers of DNA methylation. These mutations drive alterations in the epigenome which, in turn, can establish the dysregulated cellular phenotypes that have become known as the hallmarks of cancer (3) . Although many principles of chromatin regulation have been elucidated in cultured cancer cells, epigenomic studies of primary tumors are especially valuable, capturing the genuine ecosystem of heterotypic tumor and stromal cell interactions and the impacts of factors in the tumor microenvironment such as hypoxia, acidosis, and matrix stiffness (4) . TCGA has carried out targeted DNA methylation profiling of more than 10,000 samples and, more recently, whole-genome bisulfite sequencing (WGBS) of 39 TCGA tumor samples (5) . This data-rich resource has identified cancer-specific differentially methylated regions, providing an unprecedented view of epigenetic heterogeneity in cancer. Integration of DNA methylation and additional TCGA data types has enabled the prediction of functional regulatory elements (6) (7) (8) and the identification of previously unknown cancer subtypes (9) (10) (11) (12) (13) . Additional work has identified cancer-relevant variable enhancer loci by using histone modifications (14) and enhancer RNA sequencing (15) . These studies represent, to date, the largest genome-wide epigenomic profiling efforts in primary human cancer samples.
Recently, the advent of the assay for transposaseaccessible chromatin using sequencing (ATAC-seq) (16) has enabled the genome-wide profiling of chromatin accessibility in small quantities of frozen tissue (17) . Because accessible chromatin is a hallmark of active DNA regulatory elements, ATAC-seq makes it possible to assess the gene regulatory landscape in primary human cancers. Combined with the richness of diverse, orthogonal data types in TCGA, the chromatin accessibility landscape in cancer provides a key link between inherited and somatic mutations, DNA methylation, long-range gene regulation, and, ultimately, gene expression changes that affect cancer prognosis and therapy.
Results

ATAC-seq in frozen human cancer samples is highly robust
We profiled the chromatin accessibility landscape for 23 types of primary human cancers, represented by 410 tumor samples derived from 404 donors from TCGA (protocol S1). These 23 cancer types are representative of the diversity of human cancers (Fig. 1A and data S1 ). From the 410 tumor samples, we generated technical replicates from 386 samples, yielding 796 genome-wide chromatin accessibility profiles (data S1). Given the size of this cohort, we first ensured that all generated ATAC-seq data could be uniquely mapped to the expected donor through comparison with single-nucleotide polymorphism (SNP) genotyping calls ( fig. S1A) . In all samples, the genotype from the ATAC-seq data generated in this study correlated most highly with previously published genotyping array data for the expected donor compared with that of all other 11,126 TCGA donors. All ATAC-seq data included in this study passed a minimum threshold of enrichment of signal over background ( fig. S1 , B to D, and data S1) with most samples showing a characteristic fragment size distribution with clear nucleosomal periodicity ( fig. S1E ). With this high-quality set of 410 tumor samples, we identified 562,709 reproducible (observed in more than one replicate) pan-cancer Cancer chromatin accessibility extends the dictionary of DNA regulatory elements
The pan-cancer and cancer type-specific peak sets generated in this study enabled quantification of the number of DNA regulatory elements identified. To do this, we compared the regions defined by our pan-cancer and cancer type-specific peak sets to the regions defined by the Roadmap Epigenomics Project deoxyribonuclease I hypersensitive sites sequencing (DNase-seq) studies (18) , finding a median of 34.4% overlap between the cancer type-specific peak sets and the various Roadmap tissue-type peak sets, with the strongest overlap occurring in the expected combinations ( Fig. 1C and data S3). In total, about 65% of the pan-cancer peaks identified in this study had overlap with previously observed regulatory elements, highlighting both the consistency of our results with published datasets and the large number of additional putative regulatory elements observed in this study (Fig. 1C) (Fig. 1D ). This trend is consistent across different samples of the same cancer type, as shown for COAD and KIRC (Fig. 1E) and is similar to the regulation observed in the HOXD locus (20) . Genome-wide association studies (GWAS) have identified numerous inherited risk loci for cancer susceptibility. However, many of these SNPs reside in the noncoding genome within known DNA regulatory elements. In the MYC locus, we identify known sites of chromatin accessibility, including peaks surrounding functionally validated GWAS cancer susceptibility SNPs (rs6983267 and rs35252396; Fig. 1 , D and E). SNP rs6983267 is associated with increased susceptibility to colon adenocarcinoma and prostate adenocarcinoma (PRAD) (21) (22) (23) , consistent with the presence of focal chromatin accessibility in these cancer types. However, SNP rs6983267 has not been previously associated with breast cancer or any squamous tumor types, which also have strong chromatin accessibility at this regulatory element in our ATAC-seq data (Fig. 1D) . Similarly, SNP rs35252396 has been associated with KIRC and, in our data, shows strong accessibility in samples from kidney cancer types as well as breast and thyroid carcinoma, suggesting a potential role for these SNPs in previously unappreciated cancer contexts.
To visualize global patterns from our diverse ATAC-seq datasets, we performed Pearson correlation hierarchal clustering on distal and promoter elements ( Fig. 2A) . We found that distal elements exhibited a greater specificity and wider dynamic range of activity in association with cancer types, whereas promoter element accessibility was less cancer type-specific and showed similar patterns of correlation to global gene expression, as measured by RNA-seq ( Fig.  2A) . This functional specificity of distal regulatory elements was also previously observed in healthy tissues and in development (24, 25) . Using t-distributed stochastic neighbor embedding (26) (t-SNE; Fig. 2B ) and density clustering (27) (fig. S2A ), we identified 18 distinct clusters, which we labeled based on the observed cancer-type enrichment ( fig. S2B and data S3). We found strong concordance between this ATAC-seq-based clustering and the published multiomic iCluster scheme using TCGA mRNA-seq, microRNA (miRNA)-seq, DNA methylation, reverse-phase protein array (RPPA), and DNA copy number data (28) (Fig. 2, C and D) . Comparing this clustering scheme to other TCGAbased clustering schemes, we observed the strongest concordance of our ATAC-seq clustering scheme with mRNA and cancer type (Fig. 2E) . This is consistent with the connection of chromatin accessibility to transcriptional output and the observation that ATAC-seq is strongly cell type-specific. Multiple observations can be made from these clusters: (i) Some cancer types split into two distinct clusters such as breast cancer (i.e., basal and nonbasal) and esophageal cancer (i.e., squamous and adenocarcinoma), (ii) cancer samples derived from the same tissue type often group together [i.e., kidney renal papillary cell carcinoma (KIRP) and KIRC], and (iii) some cancers group together across tissues as observed for squamous cell types (Fig. 3A and  fig. S2B ).
Cluster-specific regulatory landscapes identify patterns of transcription factor usage and DNA hypomethylation Grouping of samples into defined clusters enables the determination of patterns in chromatin accessibility that are unique to each cluster. Using a framework that we term "distal binarization," we identified the distal regulatory elements that are accessible only in a single cluster or small group of clusters (Fig. 3B, fig. S2C , and data S4). Of the 516,927 pan-cancer distal elements, 203,260 were found to be highly accessible in a single cluster or group of clusters (up to four clusters). These cluster-specific peak sets are enriched for motifs of transcription factors (TFs) with correlated gene expression that are known to be important for cancer and tissue identity (Fig. 3C, fig. S2D , and data S4). These include the androgen receptor (AR) in prostate cancer, forkhead box A1 (FOXA1) in nonbasal breast cancer, and melanogenesis-associated transcription factor (MITF) in melanoma. Moreover, these cluster-specific peak sets are enriched for known GWAS SNPs that are associated with cancers of the corresponding type ( fig. S2E and data S5), highlighting that cancer-related GWAS SNPs tend to be located within or near cancer type-specific regulatory elements. The concordance of GWAS risk loci and cancer chromatin state has often been evaluated using cancer cell lines in the past, and our work provides a foundational map to evaluate noncoding GWAS SNPs in primary human cancers.
Consistent with published reports (12, 18, 29, 30) , the degree of DNA methylation was anticorrelated with chromatin accessibility at regulatory elements, and regions lacking chromatin accessibility were more frequently methylated ( fig. S2F ). In particular, cluster-specific peak sets are hypomethylated in the relevant cancer types, though frequently methylated in other cancer types that lack accessibility in those peaks ( fig. S2G ). Consistent with these observations, which are based on DNA methylation array data, we see a strong depletion of DNA methylation at the center of both distal peaks and promoter peaks in a single patient profiled by WGBS ( fig. S2H) (5) . In our analysis of methylation levels within clusterspecific peak sets, we also identified a subgroup of brain cancers that exhibits DNA hypermethylation of peaks specific to nonbrain cancers ( fig. S2G ), likely caused by mutations in genes that affect DNA methylation, such as isocitrate dehydrogenase 1 (IDH1) ( fig. S3A) . Similarly, we found that the subset of testicular germ cell tumors that are seminomas show a pattern of genome-wide DNA hypomethylation, consistent with a published report (31) (fig. S3B ). Thus, a small number of TFs dominate the cis-regulatory landscape in each cancer type. These TFs are often the known key drivers of the respective cancer or tissue type, and TF occupancy is associated with, and possibly causes, DNA hypomethylation of the corresponding DNA elements in cancer.
De novo identification of cancer subtypes from ATAC-seq data
Given the richness of the chromatin accessibility landscape, we explored the capacity of ATAC-seq data to define molecular subtypes of cancer de novo. This analysis was limited to cancer types with sufficient available donors: BRCA (N = 74), PRAD (N = 26), and KIRP (N = 34). In KIRP, a gap statistic identified three distinct subgroups that are clearly separable by the first two principal components (Fig. 3D ). The smallest of these subgroups contains four donors with very clear differences in ATAC-seq
Corces et al., Science 362, eaav1898 (2018) 26 October 2018 4 of 13 accessibility identified by distal binarization (red coloring in Fig. 3E ). Within the set of regulatory elements that are specific to this subgroup, we found 42 ATAC-seq peaks near the MDS1 and EVI1 complex locus (MECOM) gene (Fig. 3, F and G). Notably, the high chromatin accessibility of these MECOM peaks is not related to copy number amplification, as determined by DNA copy number array data (Fig. 3H) . The expression of the MECOM gene is highly correlated with the mean ATAC-seq accessibility at these 42 ATAC-seq peaks [correlation coefficient (r) = 0.79, Fig. 3I ]. Additionally, overexpression of MECOM is significantly associated with poorer overall survival across all available KIRP data from TCGA (P = 2.2 × 10
, Cox proportional hazard test, Fig. 3J ) with a hazard ratio of 5.2 (95% confidence interval = 2.4 to 11.0). This association is more substantial than lymph node status or patient age and is independent of cancer stage (Fig. 3K) , indicating a potential prognostic role for these findings. Importantly, MECOM overexpression is not readily explained by any previously identified subgroups of KIRP, including subgroups with a CpG island methylator phenotype or mutations in the gene encoding fumarate hydratase, which have also been shown to confer poor overall survival (13) . These results suggest that MECOM activation in KIRP identifies a previously unappreciated subgroup of patients with adverse outcomes, a finding that was uncovered by notable changes in the chromatin accessibility landscape of these samples.
Similarly, we found multiple distinct subgroups of PRAD and BRCA based on K-means clustering of the top 25,000 variable distal ATACseq peaks ( fig. S3, C and D) . In PRAD, these include subgroups driven by activity of AR, tumor protein P63 (TP63), and forkhead boxfamily TFs ( fig. S3C) . From an unsupervised analysis of breast cancer, we identified motifs of known TF drivers of luminal subtype identity, such as GATA binding protein 3 (GATA3) and FOXA1, as being enriched in the peak clusters specific to a subset of luminal samples (clusters 3 and 4, fig. S3D ). We also identified a potential role for grainyhead-like (GRHL) TF motifs in basal breast cancer (32) (cluster 1, fig.  S3D ) and an overlapping role for nuclear factor I (NFI) in both basal and luminal A breast cancer (cluster 2, fig. S3D ). Additionally, ATAC-seq data can be used to identify regions of copy number amplification de novo (33) , enabling the classification of HER2-amplified cases of breast cancer ( fig. S3 , E to G).
Footprinting analysis defines TF activities in cancer
The high sequencing depth of the ATAC-seq data generated in this study (median of 56.7 million unique reads per technical replicate) enabled the profiling of TF occupancy at base-pair resolution through TF footprinting. TF binding to DNA protects the protein-DNA binding site from transposition while the displacement or depletion of one or more nucleosomes creates high DNA accessibility in the immediate flanking sequence. Collectively, these phenomena are referred to as the TF footprint. To characterize TF footprints, we adapted a recent approach (34) that quantifies the "flanking accessibility," a measure of the accessibility of the DNA adjacent to a TF motif, and "footprint depth," a measure of the relative protection of the motif site from transposition ( Fig. 4A and data S6 ). To calculate these variables, we aggregated all insertions relative to the TF motif center, genomewide ( fig. S4A ). To attempt to account for known Tn5 transposase insertion bias, we computed the hexamer frequency centered at Tn5 insertions and normalized for the expected bias at each position relative to the motif center (34) (see methods for potential limitations). Depending on the binding properties of a TF and its ability to affect local chromatin accessibility, changes in these properties would be detectable through this approach genome-wide ( fig. S4 , B and C). ChromVAR (35), a similar genome-wide approach which assesses the ability of a TF to affect flanking accessibility, identified a highly overlapping list of TFs ( fig. S4D ).
To uncover transcriptionally driven TF binding patterns, we correlated the RNA-seq gene expression of a given TF to its corresponding footprint depth and estimated flanking accessibility (data S6). A factor whose expression is sufficient to generate robust DNA binding would have a footprint depth and flanking accessibility that are significantly correlated to its gene expression [false discovery rate (FDR) < 0.1, purple dots in Fig. 4B ], such as TP63 (Fig. 4, C and D) or NK2 homeobox 1 (NKX2-1) (Fig. 4, E and F) . Increases in flanking accessibility and decreases in footprint depth are likewise accompanied by decreases in methylation (bottom of Fig. 4 , D and F), consistent with the hypothesis that methylated DNA is less likely to be bound by TFs (36) . Although footprint depth and flanking accessibility are often correlated, their divergence can suggest the modes of TF-DNA interaction. For example, factors whose expression is sufficient to cause opening of chromatin around the motif site but not to protect the motif site from transposition would be expected to only exhibit a significant correlation between gene expression and flanking accessibility (blue dots in Fig.  4B ). This pattern of correlation could be caused by effects such as rapid TF off rates or low occupancy ( fig. S4, E and F) . Conversely, a small number of TFs have expression that is only significantly correlated with footprint depth (red dots in Fig. 4B ). Though likewise rare, we also identified potential negative regulators whose expression is inversely correlated to gain of flanking accessibility and loss of footprint depth, such as the cut-like homeobox 1 (CUX1) TF (37) (Fig. 4B and fig. S4, G and H) . This is the expected behavior of repressive TFs that bind DNA and lead to compaction of the neighboring sequence. These results predicted dozens of positive and negative regulators whose expression is strongly correlated with chromatin accessibility patterns near to their corresponding motif ( fig. S4I and data S6) . Overall, our footprinting analysis identified putative TFs with activities correlated with gene expression.
Linking of DNA regulatory elements to genes predicts interactions relevant to cancer biology
The breadth and depth of this sequencing study enabled a robust association of ATAC-seq peaks with the genes that they are predicted to regulate. To do this, we implemented a strategy based on the correlation of ATAC-seq accessibility and gene expression across all samples (Fig. 5A, N = 373 with matched RNA-seq and ATAC-seq). Because promoter capture Hi-C data suggested that >75% of three-dimensional (3D) promoter-based interactions occur within a 500-kilobase pair (kbp) distance (38), we restricted the length scale of this analysis to 500 kbp to avoid spurious predictions. Using a conservative FDR cutoff of 0.01, we identified 81,323 unique links between distal ATAC-seq peaks and genes ( Fig. 5B and data S7) . Some of these links are driven by correlation across many cancer types (Fig. 5 , C to E), whereas 70% are strongly driven by one cluster (Fig. 5F and data S7). To derive a final list of peak-to-gene links (Fig. 5B) , putative links were filtered against (i) links whose correlation is strongly driven by DNA copy number amplification ("CNA"; fig. S5 , A and B), (ii) regions with broad and high local correlation ("diffuse"; fig. S5 , B and C), and (iii) links involving an ATAC-seq peak that overlaps the promoter of any gene (Fig. 5G) . As expected, the histogram of distances between a peak and its target gene decays sharply with distance (39) (Fig. 5H ). The expression of most genes is correlated with the activity of fewer than five different peaks (Fig. 5I) , whereas most peaks are predicted to interact with a single gene (Fig. 5J) . Additionally, this analysis found that only 24% of predicted links occur between an ATAC-seq peak and the nearest gene, indicating that the majority of predicted interactions skip over one or more genes and would not be possible to predict from primary sequence alone (Fig. 5K) . In total, we predicted at least one peakto-gene link for 8552 protein-coding genes, accounting for nearly half of all protein-coding genes in the human genome, including 48% of the curated Catalogue of Somatic Mutations in Cancer (COSMIC) cancer-relevant genes (data S7).
In addition to predicting peak-to-gene links across cancer types, we also predicted peak-togene links within breast cancer (N = 74 donors), identifying 9711 unique peak-to-gene links ( fig. S5D and data S7). Of these links, 36% were also identified in our analysis of all cancer types ( fig. S5E ). Particularly important in these BRCAspecific links was the contribution of recurrent DNA CNA as a strong driver for spurious peakto-gene correlation (Fig. 5G) . These false-positive associations were removed through the use of published TCGA DNA copy number array data and a local correlation correction model, as mentioned above (see methods). The final predicted BRCA-specific links follow a similar distance distribution and peak-to-gene linking specificity as observed in the pan-cancer predicted links ( fig. S5, F to I ).
Many of these predicted peak-to-gene links occur in clusters where multiple nearby peaks are predicted to be linked to the same gene, indicating that these clusters of peak-to-gene links may function as part of a single regulatory unit or enhancer. Extending the width of the linked ATAC-seq peaks to 1500 bp allows for joining of these peaks into defined merged putative enhancer units ( fig. S5J ). This resulted in a total of 58,092 pan-cancer and 7622 BRCAspecific enhancer-to-gene links (data S7).
Validation and utility of predicted links between distal elements and genes
To verify a regulatory interaction for the predicted peak-to-gene links, we used a CRISPR interference (CRISPRi) (40) strategy using a catalytically dead Cas9 (dCas9) fused to a Kruppelassociated box (KRAB) domain, which mediates focal heterochromatin formation and functional silencing of noncoding DNA regulatory elements (Fig. 6A) . In this way, targeting the distal peak region of a predicted peak-to-gene link would be expected to cause a decrease in the expression of the linked gene, located tens to hundreds of kilobases away. CRISPRi of a predicted distal regulatory element linked to BCL2 (164 kbp, Fig. 5C ) led to a significant reduction in BCL2 gene expression in the luminal-like breast cancer MCF7 cell line but not in the basal-like MDA-MB-231 cell line (Fig. 6B) , consistent with the role of BCL2 as a luminal-specific survival factor (41) . Similarly, CRISPRi of a distal regulatory element linked to the SRC oncogene (−49 kbp, Fig. 5D ) led to a significant reduction in gene expression in both MCF7 cells and MDA-MB-231 cells (Fig. 6B) . On a genome-wide scale, the predicted BRCA-specific peak-to-gene links show a strong enrichment in 3D chromosome conformation data from MDA-MB-231 cells (42) , providing further support for our link prediction strategy (Fig. 6C) . Moreover, we found that, of the peak-to-gene links predicted from BRCA ATAC-seq data that are also associated with a DNA methylation array CpG probe, 35% overlap with links predicted jointly from DNA methylation array and RNA-seq data in an ELMER analysis (8, 43) of the complete TCGA BRCA dataset (N = 858 tumors) (P << 0.001; Fig. 6D,  fig. S6A , and data S8). These overlaps contain many luminal-specific and basal-specific links Similarly, previous work has leveraged TCGA RNA-seq data to infer transcriptional networks that consist of regulons, each of which is based on a TF regulator and its associated positive and negative target genes ( fig. S7A) regulon, every donor in the cohort can be assigned a positive, undefined, or negative regulon activity as measured by a differential enrichment score (dES) (45) . Certain patterns of chromatin accessibility are expected on the basis of the target gene set and dES status of the donor ( fig. S7B ). For example, in donors with positive dES, chromatin at sites linked to positive target genes should be more accessible, whereas chromatin at sites linked to negative targets should be less accessible ( fig. S7B) . Examination of the estrogen receptor 1 (ESR1) regulon in the 74 BRCA donors profiled in this study identified 482 ATAC-seq distal peak-to-gene links corresponding to 124 ESR1 target genes ( fig. S7C and data S8). Accessibility at these peaks is strongly concordant with expectations, further supporting the predicted links (P < 1 × 10
, fig. S7D ). Examination of this regulon across all TCGA BRCA donors (N = 1082) showed a significant difference in overall survival between ESR1 dESpositive and -negative samples ( fig. S7, E and F) .
Together, pan-cancer and BRCA-specific peakto-gene links further informed cancer-related GWAS polymorphisms, allowing the linkage of SNPs to putative gene targets with about 65% of all GWAS polymorphisms targeting a gene other than the closest gene on the linear genome (data S5). SNPs falling within peak-togene links were predicted to act on important cancer-related genes, including master regulators of cancer and tissue identity such as NKX2-1 ( fig. S7G) and TP63 (fig. S7H) . Focusing specifically on the BRCA peak-to-gene links for which published 3D chromosome conformation data are available, we found clear examples of GWAS SNPs interacting with distant, non-neighboring genes, such as OSR1 (Fig. 6E and fig. S7I ). Moreover, overlapping of the pan-cancer and breast cancer-specific peak-to-gene links with expression quantitative trait loci (eQTLs, where genetic variation at noncoding elements is associated with gene expression differences) from the Genotype-Tissue Expression (GTEx) project showed significant overlap in almost all comparisons (N = 44 of 48 comparisons) ( fig. S7J and data S5). These results underscored our ability to use these predicted peak-to-gene links to generate key insights into published data and inform poorly understood aspects of cancer biology.
Identification of DNA regulatory elements related to immunological response to cancer
Of particular interest to current cancer therapy, immune infiltrates represent a substantial Corces et al., Science 362, eaav1898 (2018) 26 October 2018 8 of 13 contribution to the overall tumor composition in solid tumors (46) (47) (48) . We reasoned that infiltrating immune cells could contribute to our ATAC-seq data, both through actions on tumor cells and through increased chromatin accessibility at known immune-specific regulatory elements. Leveraging published ATAC-seq datasets from the human hematopoietic system (25) and data generated here from human dendritic cell subsets (Fig. 6F) , we characterized each of our linked peaks by comparing its accessibility in immune cell types to its accessibility in bulk cancer samples (Fig. 6G) . We reasoned that peaks that are more accessible in immune cells compared with our cancer cohort might be generated from immune cells associated with the tumor tissue (Fig. 6G) . Additionally, we correlated each linked peak to the cytolytic activity score (49) of the tumor. The cytolytic activity score is based on the log-average gene expression of granzyme A and perforin 1, two CD8 T cell-specific markers. Linked peaks that exhibit high correlation to cytolytic activity might also be considered to be related to immune infiltration. Combining these two metrics, we identified peak-to-gene links expected to be highly relevant to immune infiltration, including links to genes relevant to antigen presentation and T cell response (Fig. 6H and data S9) . The accessibility of these peak-to-gene links that were predicted to be immune-related is highly correlated with computationally predicted metrics of immune infiltration (46, 47) and inversely correlated with tumor purity (48) (Fig. 6I) . One notable linked gene is programmed death ligand 1 (PDL1, also known as CD274), a key mediator of immune evasion by cancer and an important target for cancer immunotherapy. PDL1 is linked to four putative distal regulatory elements that exhibit distinct chromatin accessibility across cancer types and are located as far as 43 kbp away from the PDL1 transcription start site (Fig. 6, J and K) . CRISPRi of each of these four putative PDL1 regulatory elements significantly decreased, but did not abrogate, the expression of PDL1 mRNA in at least one of the two breast cancer cell lines tested (MCF7 and MDA-MB-231 cells, Fig. 6L ). These results support a model where the expression of PDL1 is affected by the combined activity of multiple distal regulatory elements.
Identification of cancer-relevant noncoding mutations
In addition to identifying gene regulatory interactions in cancer, ATAC-seq combined with whole-genome sequencing (WGS) can be used to identify regulatory mutations driving cancer initiation and progression. For example, if a noncoding somatic mutation causes the generation of a TF binding site, this mutation could lead to an increase in chromatin accessibility in cis and a concomitant increase in the observed frequency of the mutant allele in ATACseq as compared with that in WGS (Fig. 7A) . Similarly, a mutation that inactivates a TF binding site can lead to a decrease in chromatin accessibility and a concomitant decrease in the observed frequency of the mutant allele. If such mutations in regulatory elements were to be functional in cancer, we might also expect that they increase or decrease chromatin accessibility beyond the expected distribution observed in nonmutated samples. From the 404 donors profiled in this study, high-depth WGS data was available for 35 donors across 10 cancer types. These 35 donors had 374,705 called somatic mutations, with 32,696 falling within annotated ATAC-seq peaks and 2259 having at least 30 reads in both ATAC-seq and WGS data (data S10). Among these mutations were three separate occurrences of telomerase reverse transcriptase (TERT) gene promoter mutations (Fig. 7B) , previously shown to generate de novo E26 transformation-specific (ETS) motif sites. ATAC-seq is especially well suited to identifying these TERT promoter mutations because the variant allele frequency is skewed owing to the increase in accessibility on the mutant allele ( fig. S8A) . Compared with the publicly available exome sequencing data from TCGA, where the TERT capture probes do not extend into the promoter region, ATAC-seq provided significantly
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, fig. S8B ). Of the three TERT promoter mutations identified in the subset of donors with matched WGS, one mutation, in particular, leads to a significant increase in accessibility compared to the other nonmutated members of that cancer type (FDR < 0.0001, blue dot in Fig. 7 , B and C). As expected, this increase in TERT promoter accessibility is associated with a concomitant increase in TERT gene expression (blue dot in Fig. 7C ). TERT promoter mutations, however, are not the only way to increase TERT gene expression, because high TERT expression can also be observed in samples without identifiable TERT promoter mutations (Fig. 7C) . Consistent with a previous report (50) , differential motif analysis at the site of this TERT promoter mutation identified E74-like ETS transcription factor 1 (ELF1) or ELF2 as the TF that likely binds to the de novo ETS motif ( fig. S8C ). In addition, we identified several mutations overlapping CCCTC-binding factor (CTCF) motif occurrences that are associated with decreased accessibility at that site ( fig. S8, D and E) . However, these mutations were relatively rare and often had only small effects on the accessibility of the CTCF motif site despite a known enrichment of somatic mutations in CTCF motif sites in cancer (51, 52) .
In addition to known TERT promoter mutations, integrative analysis of WGS and ATACseq data uncovered a mutation upstream of the FYVE RhoGEF and PH domain-containing 4 (FGD4) gene, a regulator of the actin cytoskeleton and cell shape. This mutation occurs in a bladder cancer sample where the variant allele frequency observed in ATAC-seq is markedly higher than the variant allele frequency observed in WGS (Fig. 7B ). This mutation is associated with a significant increase in accessibility compared to other bladder cancer samples in this cohort (Fig. 7, B and D) and is accompanied by a similar increase in FGD4 mRNA (Fig. 7D) . Moreover, this mutation upstream of the FGD4 gene (referred to as eFGD4 for enhancer FGD4) leads to a level of accessibility that is higher than any of the other samples profiled by ATAC-seq in this study ( fig. S8F ) and a level of FGD4 gene expression that is in the top 3% of all bladder cancer samples in TCGA ( fig. S8G) . As estimated by WGS data, this eFGD4 mutation is present in a subclone comprising about 13% of the tumor (Fig. 7E) ; however, the mutant allele is present in 96% of all ATAC-seq reads spanning this locus (Fig. 7E) , demonstrating a strong preference for accessibility on the mutant allele. This eFGD4 mutation is analogous to, but potentially more potent than, the TERT promoter mutation described above (Fig. 7E) . In the case of the eFGD4 mutation, this dramatic allele bias occurs because chromatin at this locus is not normally accessible in any of the bladder cancer samples profiled in this study (gray dots and tracks in Fig. 7 , D and F) but becomes highly accessible in the context of the eFGD4 mutation (purple dot and track in Fig. 7, D and F) . Differential motif analysis identified NKX factor motifs as the most strongly enriched in the sequence corresponding to the eFGD4 mutation (Fig. 7G) , where a C-to-T transition at position two generated a perfect NKX2-8 motif de novo from a latent site (Fig. 7H) . RNA-seq data from the mutated sample identified multiple expressed NKX TFs [transcripts per million (TPM) > 0.5], nominating NKX3-1, NKX2-3, and NKX2-5 as potential mediators of this DNA binding event ( fig. S8H ). From this, we hypothesized that the eFGD4 mutation creates a de novo binding site for an NKX TF which, upon binding to the DNA, leads to a broad increase in accessibility across the entire 12-kbp region upstream of the FGD4 gene. This hypothesis was further supported by the observation that the ATAC-seq accessibility of the entire FGD4 upstream locus occurs on a single phased allele ( fig. S8I ). Moreover, separation of subnucleosomal and nucleosomespanning reads in the ATAC-seq data are consistent with protein binding at the site of the eFGD4 mutation (light blue shading in fig. S8I ). Lastly, because higher FGD4 expression is significantly associated with worse overall survival in bladder cancer (Fig. 7I and fig. S8J ), this mutation could have functional consequence in this particular cancer. Whether the eFGD4 mutation or other enhancer mutations emerge as recurrent drivers of human cancer should be addressed in future studies. Our data identified multiple additional noncoding mutations associated with a concomitant gain of chromatin accessibility and increase in RNA expression ( fig. S8 , K to Q), and we anticipate that future work will uncover mechanisms underlying this type of regulatory mutation across all cancer types.
Discussion
Here we provide an initial characterization of the chromatin regulatory landscape in primary human cancers. This dataset identified hundreds of thousands of accessible DNA elements, expanding the dictionary of regulatory elements discovered through previous large-scale efforts such as The Roadmap Epigenomics Project. The identification of these additional elements was made possible through (i) our analysis of primary cancer specimens, (ii) greater saturation of some cancer and tissue types in our dataset, or (iii) potential differences between ATAC-seq and DNase-seq platforms. Nevertheless, the high overlap between the two datasets demonstrates the robustness of both platforms and the consistency of the observed results.
The exquisite cell type-specificity of distal regulatory elements from our ATAC-seq data enabled the classification of cancer types and the discovery of previously unappreciated cancer Corces The data generated in this study fully represents the cellular complexity of primary human tumors, comprising signals from tumor cells, infiltrating immune cells, stromal cells, and other normal cell types. In many ways, this complexity is advantageous because it allows complex systems-level analyses to be performed in the future, including cellular deconvolution approaches to understand the contributions of various cell types or cell states to the overall landscape of chromatin accessibility. However, the admixed nature of this signal also highlights the need for future work to profile the chromatin accessibility of matched healthy tissues to further refine the specific changes that drive cancer. Nevertheless, the chromatin accessibility profiles generated in this study represent the largest effort to date to characterize the regulatory landscape in primary human cancer cells.
Using this data-rich resource, we identified classes of TFs whose expression leads to different patterns in TF occupancy and motif protection. By integrating RNA-seq and ATACseq, we found factors whose expression is sufficient for both motif protection and nucleosome repositioning and demonstrated this binding to be inversely correlated with the level of DNA methylation at those binding sites. Despite this strong correlation, many sites of differential chromatin accessibility do not show differential methylation, demonstrating the complementarity of these two data types, perhaps owing to the presence of intermediate chromatin states such as poised promoters or enhancers (53, 54) .
Moreover, integration of RNA-seq and ATACseq across the 373 donors with paired datasets enabled a quantitative model to link the accessibility of a regulatory element to the expression of predicted target genes. This workflow identified putative links for more than half of the protein-coding genes in the genome, informing the target genes of poorly understood GWAS SNPs and increasing our understanding of cancer gene regulatory networks. These predictions were further supported using 3D chromosome conformation data, and a subset were validated through CRISPRi experiments in breast cancer cell lines. However, profiling of chromosome conformation in primary cancer samples has not been performed on a large scale. Future work to produce maps of chromosome conformation in these or other primary cancer samples will improve our understanding of gene regulatory networks in cancer and further clarify the roles for certain GWAS-identified SNPs in cancer initiation and progression.
Lastly, through integration of WGS and ATACseq, we revealed a class of somatic mutations that occur in regulatory regions and lead to strong gains in chromatin accessibility. We demonstrated that these mutations likely lead to changes in nearby gene expression and affect genes whose expression is linked to poorer overall survival. Some of these mutations, such as those occurring in the TERT promoter, have been found to be recurrent whereas others, such as the mutation upstream of the FGD4 gene, may be rare but functionally important. Because the enhancer functions are often distributed and latent enhancer sequences are pervasive in the genome, noncoding mutations in cancer may be especially challenging and require highthroughput functional assessment. Future largerscale efforts to combine genome and epigenome sequencing will pave the way to tackling the noncoding genome in cancer.
Materials and methods summary
ATAC-seq data was generated from 410 tissue samples from the TCGA collection of primary human tumors. These samples spanned 23 different tumor types. These ATAC-seq data were used to cluster samples, identifying epigenetically defined patient subgroups. Moreover, TF regulators of cancer were defined, and footprinting of these regulators was correlated to gene expression to identify putative classes of TFs. A correlation-based model was developed to link ATAC-seq peaks to putative target genes. These putative links were validated using CRISPRibased perturbation of the peak region followed by quantification of changes in gene expression. Publicly available HiChIP data and GTEx eQTL data were further used to support genome-wide peak-to-gene linkage predictions. Lastly, WGS and ATAC-seq were combined to identify noncoding mutations that affect chromatin accessibility in an allele-specific manner. normalized counts matrices, cancer type-specific peak calls, cancer type-specific raw and normalized count matrices, and bigWig track files for all technical replicates. Raw ATAC-seq data as fastq or aligned BAM files will be made available through the NIH Genomic Data Commons portal (https://portal.gdc.cancer. gov/). ATAC-seq data corresponding to human plasmacytoid dendritic cells and myeloid dendritic cells (the only non-TCGA data generated here) is available through SRA BioProject PRJNA491478. The ATAC-seq peak accessibility and computed peak-to-gene linkage predictions are publicly available for interactive visualization and exploration at the UCSC Xena Browser (https://atacseq.xenahubs.net). 
